Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.
- DOI
- 10.1186/s12894-026-02264-5
- Published
- 2026 Jul 20
- Container
- BMC urology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12894-026-02264-5,
title = {Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.},
author = {Tekin MD and Erdoğan AP and Şahbazlar M and Faraşat M and Pehlivan FS and Ekinci F},
year = {2026},
journal = {BMC urology},
doi = {10.1186/s12894-026-02264-5},
url = {https://doi.org/10.1186/s12894-026-02264-5}
}RIS
TY - JOUR TI - Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report. AU - Tekin MD AU - Erdoğan AP AU - Şahbazlar M AU - Faraşat M AU - Pehlivan FS AU - Ekinci F PY - 2026 JO - BMC urology DO - 10.1186/s12894-026-02264-5 UR - https://doi.org/10.1186/s12894-026-02264-5 ER -
APA
MD, T., AP, E., M, Ş., M, F., FS, P., & F, E. (2026). Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report.. BMC urology. https://doi.org/10.1186/s12894-026-02264-5
Source records
- pubmed · retrieved 2026-09-27T10:51:32.933Z